Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Oral tazarotene delivers lasting results for plaque psoriasis
Washington - According to a poster study presented at the annual American Academy of Dermatology meeting, oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.) gives patients with plaque psoriasis significant improvements that continue after treatment stops. The blinded, placebo-controlled multicenter study of approximately 700 patients shows that oral tazarotene delivers several advantages over existing alternatives for treating plaque psoriasis.
Related Videos
Related Content
